Curosurf (poractant): Reviews and patient testimonials
Medication indications
Curosurf
For the treatment of Respiratory Distress Syndrome (RDS) or hyaline membrane disease in newborn babies with birth weight over 700g.
Prophylactic use in premature infants between 24 and 31 weeks estimated gestational age at risk from RDS or with evidence of surfactant deficiency.
Molecule: poractant
Patients' opinions on Curosurf
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.